Pinion Investment Advisors LLC Takes $1.41 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Pinion Investment Advisors LLC bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 75,000 shares of the biotechnology company's stock, valued at approximately $1,410,000. Pinion Investment Advisors LLC owned 0.06% of Arrowhead Pharmaceuticals at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ARWR. R Squared Ltd bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth approximately $38,000. Van ECK Associates Corp raised its position in Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 1,250 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company's stock worth $88,000 after acquiring an additional 788 shares during the period. KBC Group NV boosted its stake in shares of Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock worth $98,000 after acquiring an additional 1,644 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at $149,000. Institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock traded down $0.70 on Friday, hitting $16.97. 1,354,112 shares of the company traded hands, compared to its average volume of 1,987,845. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $16.57 and a 52 week high of $35.47. The business has a 50-day simple moving average of $19.43 and a 200 day simple moving average of $20.58. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The stock has a market capitalization of $2.14 billion, a P/E ratio of -3.28 and a beta of 0.92.

Remove Ads

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). Research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, Director William D. Waddill sold 3,748 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $21.90, for a total value of $82,081.20. Following the sale, the director now owns 44,125 shares in the company, valued at approximately $966,337.50. The trade was a 7.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the stock in a transaction on Friday, December 27th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. Following the transaction, the director now owns 36,740 shares of the company's stock, valued at $734,800. This trade represents a 7.20 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 280,765 shares of company stock valued at $5,227,313. 4.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently commented on ARWR. StockNews.com raised Arrowhead Pharmaceuticals to a "sell" rating in a report on Friday, December 20th. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. B. Riley reiterated a "buy" rating and set a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. HC Wainwright reissued a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.